Page 23 - Recursion Pharmaceuticals News Today

Its future could be bright, but don't get too attached to its successes right now.

Ginkgo Bioworks, Recursion Pharmaceutical, and Eli Lilly are cashing in on the AI-Biotech trend of tomorrow using the big data of today.

Major pharmaceutical companies are increasingly turning to artificial intelligence (AI) to revolutionize drug development processes

Cathie Wood is loading up on these healthcare stocks.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) insider Shafique Virani sold 18,000 shares of the firm’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $8.66, for a total value of $155,880.00. Following the transaction, the insider now directly owns 140,351 shares in the company, valued […]

The high cost of developing drugs makes the use of artificial intelligence a natural fit for pharmaceutical companies.

They're both liable to grow by a lot, but one of them is a safer bet in the near term.

Find out why analysts have such high expectations for these stocks.

It’s been a good year so far for Cathie Wood. Representing a meaningful turnaround after what can be described as a two-year post-pandemic comedown, her flagship ARKK Innovation fund (ARKK) is up by 46% year-to-date, putting the main indexes’ performances in the shade. That said, given Wood’s penchant for the risky and outré, not all the stocks that make up the various funds under the Ark Invest banner are doing well right now. Some have underperformed recently and look...

This biotech could still be a long way from having a drug on the market in 2026.